Last C$3.01 CAD
Change Today -0.29 / -8.79%
Volume 277.0
As of 10:25 AM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

fennec pharmaceuticals inc (FRX) Snapshot

Open
C$3.01
Previous Close
C$3.30
Day High
C$3.01
Day Low
C$3.01
52 Week High
05/27/14 - C$7.77
52 Week Low
12/23/14 - C$2.01
Market Cap
31.9M
Average Volume 10 Days
3.1K
EPS TTM
C$-0.21
Shares Outstanding
10.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FENNEC PHARMACEUTICALS INC (FRX)

Related News

No related news articles were found.

fennec pharmaceuticals inc (FRX) Related Businessweek News

No Related Businessweek News Found

fennec pharmaceuticals inc (FRX) Details

Fennec Pharmaceuticals Inc., together with its subsidiaries, operates as a biopharmaceutical company with a portfolio of product candidates under development for use in the treatment of cancer. Its lead product candidates include Sodium Thiosulfate, a water soluble thiol compound, which is in phase III clinical trials that act as a chemical reducing agent for the prevention of cisplatin induced hearing loss or ototoxicity in children; and Eniluracil, an oral irreversible dihydropyrimidine dehydrogenase inhibitor for the rapid break down of 5-FU in the body, which has completed phase II clinical trials for the treatment of metastatic breast cancer. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

1 Employees
Last Reported Date: 05/14/14
Founded in 1996

fennec pharmaceuticals inc (FRX) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $140.0K
Interim Chief Financial Officer
Total Annual Compensation: $26.5K
Consultant
Total Annual Compensation: $71.5K
Compensation as of Fiscal Year 2013.

fennec pharmaceuticals inc (FRX) Key Developments

Fennec Pharmaceuticals Inc. Announces Independent Data Monitoring Committee Recommends the Continuation of SIOPEL 6 Phase 3 Clinical Trial

Fennec Pharmaceuticals Inc. announced that the IDMC overseeing the SIOPEL 6 phase 3 clinical trial recommended that the study be continued as planned. The IDMC has been established to assess any potential concern of an adverse effect of STS on the efficacy of the cisplatin chemotherapy and to review safety according to protocol pre-specified patient numbers. Previously, the IDMC reached similar conclusion after reviewing the safety of 20, 40, 60 and 80 patients and their current recommendation on 100 patients to continue the clinical trial represents the last and final safety review. SIOPEL 6 is a multi-centre open label randomized phase 3 study evaluating the efficacy of STS in reducing ototoxicity in patients receiving cisplatin monotherapy for standard risk hepatoblastoma. From the beginning of 2007 to the end 2014, 45 sites from 12 countries enrolled 113 evaluable patients. The study is closed to recruitment and all protocol pre-specified IDMC safety reviews are now complete. The primary efficacy hearing endpoint analysis can be performed once patients have reached 3.5 years of age and an audiometry test can be carried out.

Fennec Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Fennec Pharmaceuticals Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. The company reported a net loss from operations of $0.6 million which excludes a $0.6 million non-cash gain on derivatives for the third quarter ended September 30, 2014, compared to a net loss from operations of $0.1 million excluding the non-cash loss on derivatives of $1.7 million in the same period 2013. Loss from operations was $0.619 million against $0.051 million a year ago. Net income was $0.380 million or $0.03 diluted per common share against loss of $1.766 million or $0.21 basic and diluted per common share a year ago. For the nine month period ended September 30, 2014, the company reported a net loss from operations of $2.1 million excluding the $1.9 million non-cash loss on derivatives, compared to a net loss from operations of $1.5 million excluding the non-cash gain of $2.3 million in the same period in 2013. Loss from operations was $2.086 million against $1.515 million a year ago. Net loss of $3.564 million or $0.36 basic and diluted per common share against income of $0.734 million or $0.09 basic and diluted per common share a year ago.

Adherex Technologies Inc. has Changed its Ticker to ADHXD from ADHX.F

Effective September 05, 2014, Adherex Technologies Inc. changed its Pink Sheets LLC stock ticker symbol to ADHXD from ADHX.F.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FRX:CN C$3.01 CAD -0.29

FRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FRX.
View Industry Companies
 

Industry Analysis

FRX

Industry Average

Valuation FRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FENNEC PHARMACEUTICALS INC, please visit www.fennecpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.